193 related articles for article (PubMed ID: 14663001)
1. Adenosine-dopamine interactions: development of a concept and some comments on therapeutic possibilities.
Fredholm BB; Svenningsson P
Neurology; 2003 Dec; 61(11 Suppl 6):S5-9. PubMed ID: 14663001
[TBL] [Abstract][Full Text] [Related]
2. Regulation of the phosphorylation of the dopamine- and cAMP-regulated phosphoprotein of 32 kDa in vivo by dopamine D1, dopamine D2, and adenosine A2A receptors.
Svenningsson P; Lindskog M; Ledent C; Parmentier M; Greengard P; Fredholm BB; Fisone G
Proc Natl Acad Sci U S A; 2000 Feb; 97(4):1856-60. PubMed ID: 10677546
[TBL] [Abstract][Full Text] [Related]
3. Purinergic signaling in Parkinson's disease. Relevance for treatment.
Navarro G; Borroto-Escuela DO; Fuxe K; Franco R
Neuropharmacology; 2016 May; 104():161-8. PubMed ID: 26211977
[TBL] [Abstract][Full Text] [Related]
4. Behavioral control by striatal adenosine A
Taura J; Valle-León M; Sahlholm K; Watanabe M; Van Craenenbroeck K; Fernández-Dueñas V; Ferré S; Ciruela F
Genes Brain Behav; 2018 Apr; 17(4):e12432. PubMed ID: 29053217
[TBL] [Abstract][Full Text] [Related]
5. Caffeine as a psychomotor stimulant: mechanism of action.
Fisone G; Borgkvist A; Usiello A
Cell Mol Life Sci; 2004 Apr; 61(7-8):857-72. PubMed ID: 15095008
[TBL] [Abstract][Full Text] [Related]
6. Discovery of indolylpiperazinylpyrimidines with dual-target profiles at adenosine A2A and dopamine D2 receptors for Parkinson's disease treatment.
Shao YM; Ma X; Paira P; Tan A; Herr DR; Lim KL; Ng CH; Venkatesan G; Klotz KN; Federico S; Spalluto G; Cheong SL; Chen YZ; Pastorin G
PLoS One; 2018; 13(1):e0188212. PubMed ID: 29304113
[TBL] [Abstract][Full Text] [Related]
7. Targeting adenosine A2A receptors in Parkinson's disease.
Schwarzschild MA; Agnati L; Fuxe K; Chen JF; Morelli M
Trends Neurosci; 2006 Nov; 29(11):647-54. PubMed ID: 17030429
[TBL] [Abstract][Full Text] [Related]
8. Genetic deletion of GPR52 enhances the locomotor-stimulating effect of an adenosine A
Nishiyama K; Suzuki H; Maruyama M; Yoshihara T; Ohta H
Brain Res; 2017 Sep; 1670():24-31. PubMed ID: 28583861
[TBL] [Abstract][Full Text] [Related]
9. The dopamine D2 and adenosine A2A receptors: past, present and future trends for the treatment of Parkinson's disease.
Jorg M; Scammells PJ; Capuano B
Curr Med Chem; 2014; 21(27):3188-210. PubMed ID: 24533801
[TBL] [Abstract][Full Text] [Related]
10. Increased sensitivity in the interaction of the dopaminergic/adenosinergic system at the level of the adenylate cyclase activity in the striatum of the "weaver" mouse.
K B; V T; N P; M M; N M; F A
Neurochem Int; 2016 Oct; 99():233-238. PubMed ID: 27498335
[TBL] [Abstract][Full Text] [Related]
11. Cocaine exposure modulates dopamine and adenosine signaling in the fetal brain.
Kubrusly RC; Bhide PG
Neuropharmacology; 2010 Feb; 58(2):436-43. PubMed ID: 19765599
[TBL] [Abstract][Full Text] [Related]
12. Adenosine A2A-D2 receptor-receptor interactions in putative heteromers in the regulation of the striato-pallidal gaba pathway: possible relevance for parkinson's disease and its treatment.
Beggiato S; Antonelli T; Tomasini MC; Borelli AC; Agnati LF; Tanganelli S; Fuxe K; Ferraro L
Curr Protein Pept Sci; 2014; 15(7):673-80. PubMed ID: 25175458
[TBL] [Abstract][Full Text] [Related]
13. Adenosine A2a receptor antagonists attenuate striatal adaptations following dopamine depletion.
Peterson JD; Goldberg JA; Surmeier DJ
Neurobiol Dis; 2012 Jan; 45(1):409-16. PubMed ID: 21964253
[TBL] [Abstract][Full Text] [Related]
14. Receptor heteromerization in adenosine A2A receptor signaling: relevance for striatal function and Parkinson's disease.
Fuxe K; Agnati LF; Jacobsen K; Hillion J; Canals M; Torvinen M; Tinner-Staines B; Staines W; Rosin D; Terasmaa A; Popoli P; Leo G; Vergoni V; Lluis C; Ciruela F; Franco R; Ferré S
Neurology; 2003 Dec; 61(11 Suppl 6):S19-23. PubMed ID: 14663004
[TBL] [Abstract][Full Text] [Related]
15. Striatal plasticity at the network level. Focus on adenosine A2A and D2 interactions in models of Parkinson's Disease.
Tanganelli S; Sandager Nielsen K; Ferraro L; Antonelli T; Kehr J; Franco R; Ferré S; Agnati LF; Fuxe K; Scheel-Krüger J
Parkinsonism Relat Disord; 2004 Jul; 10(5):273-80. PubMed ID: 15196505
[TBL] [Abstract][Full Text] [Related]
16. Progress in pursuit of therapeutic A2A antagonists: the adenosine A2A receptor selective antagonist KW6002: research and development toward a novel nondopaminergic therapy for Parkinson's disease.
Kase H; Aoyama S; Ichimura M; Ikeda K; Ishii A; Kanda T; Koga K; Koike N; Kurokawa M; Kuwana Y; Mori A; Nakamura J; Nonaka H; Ochi M; Saki M; Shimada J; Shindou T; Shiozaki S; Suzuki F; Takeda M; Yanagawa K; Richardson PJ; Jenner P; Bedard P; Borrelli E; Hauser RA; Chase TN;
Neurology; 2003 Dec; 61(11 Suppl 6):S97-100. PubMed ID: 14663020
[TBL] [Abstract][Full Text] [Related]
17. DARPP chocolate: a caffeinated morsel of striatal signaling.
Bastia E; Schwarzschild MA
Sci STKE; 2003 Jan; 2003(165):PE2. PubMed ID: 12527819
[TBL] [Abstract][Full Text] [Related]
18. Role of adrenoceptors in the regulation of dopamine/DARPP-32 signaling in neostriatal neurons.
Hara M; Fukui R; Hieda E; Kuroiwa M; Bateup HS; Kano T; Greengard P; Nishi A
J Neurochem; 2010 May; 113(4):1046-59. PubMed ID: 20236221
[TBL] [Abstract][Full Text] [Related]
19. Interaction of A2A adenosine and D2 dopamine receptors modulates corticostriatal glutamatergic transmission.
Tozzi A; Tscherter A; Belcastro V; Tantucci M; Costa C; Picconi B; Centonze D; Calabresi P; Borsini F
Neuropharmacology; 2007 Nov; 53(6):783-9. PubMed ID: 17889039
[TBL] [Abstract][Full Text] [Related]
20. Role of adenosine A1 receptors in the modulation of dopamine D1 and adenosine A2A receptor signaling in the neostriatum.
Yabuuchi K; Kuroiwa M; Shuto T; Sotogaku N; Snyder GL; Higashi H; Tanaka M; Greengard P; Nishi A
Neuroscience; 2006 Aug; 141(1):19-25. PubMed ID: 16750892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
